Reproduction/Androgen Disorders News

Postmenopausal women with vulvovaginal atrophy treated with intravaginal prasterone for at least 12 weeks were nearly 50% less likely to develop a urinary tract infection compared with untreated women, researchers reported in Menopause.

Use of menopausal hormone therapy among midlife active-duty servicewomen in the U.S. is twice as high as the general population but lower than women veterans, suggesting those who may derive the most benefit from HT are not receiving it.

Few researchers can claim to be a pioneer in their field quite like Teresa K. Woodruff, PhD.

Midlife women with a metabolic dysfunction-associated steatotic liver disease diagnosis were more likely to report severe or very severe hot flashes, though researchers found no direct link between the two conditions, data show.

The FDA added a boxed warning to highlight known risk for rare but serious liver injury associated with the use of fezolinetant, a nonhormonal medication indicated for treating menopausal hot flashes, according to an agency press release.

Compared with a low-fat diet, nutritional ketosis with or without exogenous ketones may positively impact self-reported menses for women, restarting or realigning menstrual cycles, according to study results published in PLOS ONE.

Women are living, on average, 5 years longer than men with an improved overall quality of life, but with an increased lifespan comes greater risk for multimorbidity, particularly after the menopause transition.

Short-term exposure to hormone therapy started within 3 years of menopause was not associated with long-term cognitive impairment or benefit, according to data from the KEEPS Continuation study.

Men with lower concentrations of sex hormone-binding globulin may be less likely to sustain a fracture than those with higher levels, according to data published in The Journal of Clinical Endocrinology & Metabolism.